MiR-200c sensitizes Olaparib-resistant ovarian cancer cells by targeting Neuropilin 1

BACKGROUND: Ovarian cancer (OC) is the most lethal gynecological malignancy and the second leading cause of cancer-related death in women. Treatment with PARP inhibitors (PARPi), such as Olaparib, has been recently introduced for OC patients, but resistance may occur and underlying mechanisms are st...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Exp Clin Cancer Res
Autors principals: Vescarelli, Enrica, Gerini, Giulia, Megiorni, Francesca, Anastasiadou, Eleni, Pontecorvi, Paola, Solito, Luciana, De Vitis, Claudia, Camero, Simona, Marchetti, Claudia, Mancini, Rita, Benedetti Panici, Pierluigi, Dominici, Carlo, Romano, Ferdinando, Angeloni, Antonio, Marchese, Cinzia, Ceccarelli, Simona
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6939329/
https://ncbi.nlm.nih.gov/pubmed/31898520
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-019-1490-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars